T lymphoblastic leukemia/lymphoma
MONDO:0003537A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells. When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia. When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)
Also known as: precursor T lymphoblastic leukemia/lymphoma, precursor T lymphoblastic lymphoma/leukemia, precursor T-lymphoblastic lymphoma/leukemia
1945 clinical trials for this condition and its sub-types, 18 tagged with T lymphoblastic leukemia/lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of T lymphoblastic leukemia/lymphoma
-
T-lymphoblastic lymphoma 32 trials
-
T-cell prolymphocytic leukemia 17 trials
-
Childhood precursor T-lymphoblastic lymphoma/leukemia 0 trials · 13 incl. sub-types
2 sub-types
-
Aggressive NK-cell leukemia 11 trials
-
Supercharged immune cells take on tough T-Cell cancers
Disease control Not yet recruitingThis Phase 2 trial tests a new treatment for aggressive T-cell blood cancers. Patients receive specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, to try to keep the cancer in remission. The study will enroll 70 adults aged 18-80 whose…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Could an antibody boost chemo for tough blood cancers?
Disease control Not yet recruitingThis large clinical trial is testing whether adding the drug daratumumab to standard chemotherapy helps children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). Daratumumab is an antibody that targets a pr…
Phase 2/3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Stem cell showdown: which transplant best keeps T-Cell cancer at bay?
Disease control Not yet recruitingThis study looks at two stem cell transplant methods—using a patient's own cells or a donor's cells—as a follow-up treatment for people with T-cell acute lymphoblastic leukemia or lymphoma who are in their first complete remission. The goal is to see which approach better prevent…
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Engineered immune cells take on tough T-Cell cancers in new trial
Disease control Not yet recruitingThis study tests a new treatment called S101 CAR-T cells for people with a type of T-cell cancer (T-LBL/ALL) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. Th…
Phase 2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC